Evidence map›Paper›PMID 38850343›Full record

ArticleInflammation research : official journal of the European Histamine Research Society ... [et al.]2024

Saccharomyces cerevisiae β-glucan improves the response of trained macrophages to severe P. aeruginosa infections.

Marta Ciszek-Lenda, Bernadeta Nowak, Grzegorz Majka, Maciej Suski, Maria Walczewska, Angelika Fedor, Edyta Golińska, Sabina Górska, Andrzej Gamian, Rafał Olszanecki and 2 more

Abstract read
In one paragraph

Article in Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Marta Ciszek-LendaDepartment of Immunology, Faculty of Medicine, Jagiellonian University Medical College, Czysta 18, Krakow, 31-121, Poland.
Bernadeta NowakDepartment of Immunology, Faculty of Medicine, Jagiellonian University Medical College, Czysta 18, Krakow, 31-121, Poland.
Grzegorz MajkaDepartment of Immunology, Faculty of Medicine, Jagiellonian University Medical College, Czysta 18, Krakow, 31-121, Poland. grzegorz.majka@uj.edu.pl.
Maciej SuskiDepartment of Pharmacology, Faculty of Medicine, Jagiellonian University Medical College, Grzegorzecka 16, Krakow, 31-53, Poland.
Maria WalczewskaDepartment of Immunology, Faculty of Medicine, Jagiellonian University Medical College, Czysta 18, Krakow, 31-121, Poland.
Angelika FedorDepartment of Immunology, Faculty of Medicine, Jagiellonian University Medical College, Czysta 18, Krakow, 31-121, Poland.
Edyta GolińskaDepartment of Microbiology, Faculty of Medicine, Jagiellonian University Medical College, Czysta 18, Krakow, 31-121, Poland.
Sabina GórskaHirszfeld Institute of Immunology and Experimental Therapy, Department of Microbiology, Laboratory of Microbiome Immunobiology, Polish Academy of Sciences, Weigla 12, Wroclaw, 53-114, Poland.
Andrzej GamianHirszfeld Institute of Immunology and Experimental Therapy, Department of Immunology of Infectious Diseases, Laboratory of Medical Microbiology, Polish Academy of Sciences, Weigla 12, Wroclaw, 53-114, Poland.
Rafał OlszaneckiDepartment of Pharmacology, Faculty of Medicine, Jagiellonian University Medical College, Grzegorzecka 16, Krakow, 31-53, Poland.
Magdalena StrusDepartment of Microbiology, Faculty of Medicine, Jagiellonian University Medical College, Czysta 18, Krakow, 31-121, Poland.
Janusz MarcinkiewiczUniversity of Agriculture, University Centre of Veterinary Medicine, Mickiewicza 24/28, Krakow, 30- 059, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

OBJECTIVE P. AERUGINOSA: (PA), the major pathogen of lung cystic fibrosis (CF), polarizes macrophages into hyperinflammatory tissue damaging phenotype. The main aim of this study was to verify whether training of macrophages with β-glucan might improve their response to P. aeruginosa infections.

methodsTo perform this task C57BL/6 mice sensitive to infections with P. aeruginosa were used. Peritoneal macrophages were trained with Saccharomyces cerevisiae β-glucan and exposed to PA57, the strong biofilm-forming bacterial strain isolated from the patient with severe lung CF. The release of cytokines and the expression of macrophage phenotypic markers were measured. A quantitative proteomic approach was used for the characterization of proteome-wide changes in macrophages. The effect of in vivo β-glucan-trained macrophages in the air pouch model of PA57 infection was investigated. In all experiments the effect of trained and naïve macrophages was compared.

resultsTrained macrophages acquired a specific phenotype with mixed pro-inflammatory and pro-resolution characteristics, however they retained anti-bacterial properties. Most importantly, transfer of trained macrophages into infected air pouches markedly ameliorated the course of infection. PA57 bacterial growth and formation of biofilm were significantly suppressed. The level of serum amyloid A (SAA), a systemic inflammation biomarker, was reduced.

conclusionsTraining of murine macrophages with S. cerevisiae β-glucan improved macrophage defense properties along with inhibition of secretion of some detrimental inflammatory agents. We suggest that training of macrophages with such β-glucans might be a new therapeutic strategy in P. aeruginosa biofilm infections, including CF, to promote eradication of pathogens and resolution of inflammation.

Indexed as

beta-GlucansBiofilmsCytokinesMice, Inbred C57BLPseudomonas aeruginosaPseudomonas InfectionsSaccharomyces cerevisiaeAnimalsCells, CulturedFemaleMacrophagesMacrophages, PeritonealMiceSerum Amyloid A Proteinbeta-GlucansCytokinesSerum Amyloid A ProteinBiofilm P. AeruginosaInflammationSaccharomyces cerevisiae β-glucanTrained macrophages

Identifiers

PMID38850343
PMCPMC11282130

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.